Pharma wants FDA’s IND reporting rule better aligned with ICH E2F

Regulatory NewsRegulatory NewsBiologics/ biosimilars/ vaccinesClinical TrialsComplianceNorth AmericaPharmaceuticalsProject managementRegulatory Intelligence/Policy